Tebipenem Pivoxil Hydrobromide Patent Expiration

Tebipenem Pivoxil Hydrobromide was first introduced by Glaxosmithkline Llc in its drug Utebzi on Jun 17, 2026.


Tebipenem Pivoxil Hydrobromide Patents

Given below is the list of patents protecting Tebipenem Pivoxil Hydrobromide, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Utebzi US10889587 Tebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of Use Feb 06, 2038 Glaxosmithkline
Utebzi US12226403 Tebipenem Pivoxil Immediate And Modified Release Oral Dosage Forms Dec 15, 2037 Glaxosmithkline



Tebipenem Pivoxil Hydrobromide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Tebipenem Pivoxil Hydrobromide Generic API Manufacturers

Given below is the list of companies who have filed for Tebipenem Pivoxil Hydrobromide generic, along with the locations of their manufacturing plants worldwide.